Search Results
Sep 04, 2026, 07:00 ET Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
developing next-generation cell therapies and antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ACE723, a GPC3-targeted dual-payload antibody-drug conjugate (ADC) developed using Acepodia's proprietary
More news about: Acepodia, Inc.
Sep 04, 2026, 07:00 ET DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES
IND in the US with a Phase 2 clinical trial protocol which has received approval to proceed by the US Food and Drug Administration (FDA), as well as sufficient pharmaceutical grade (GMP) drug product for the Phase 2 trial and all manufacturing methodology. The Phase 2 trial is designed to investigate
More news about: Dimerix Limited
Sep 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around
More news about: Insmed Incorporated
Sep 04, 2026, 04:37 ET Global Times: Xi concludes SCO summit, state visits to Kyrgyzstan, Egypt with 'solidarity, cooperation running through the trip as main theme'
additions to the SCO Charter, the regulations on the SCO Universal Center for Countering Security Challenges and Threats and the regulations on the SCO Anti-drug Center, and adopted 28 outcome documents covering such areas as security, economic and people-to-people cooperation, and organizational development,
More news about: Global Times
Sep 03, 2026, 20:54 ET Happy Soul Brings Its Functional Gummy Line to the Americas Food & Beverage Show
mysoulishappy.com*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.Media contactEli Elias, Founder
More news about: Happy Soul Nutrition
Sep 03, 2026, 17:31 ET AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Sep 03, 2026, 16:54 ET CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory
More news about: Hagens Berman Sobol Shapiro LLP
Sep 03, 2026, 16:48 ET Beverly Hills MD Dermal Repair Complex Wins Beauty Product of the Year
TikTok.* Individual results will vary.*+ These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.*Press Contact:
More news about: Beverly Hills MD
Sep 03, 2026, 16:23 ET Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
Europe at this intersection of chemistry and neurobiology," Odink added. "Parkinson's and Alzheimer's disease remain two of the hardest problems in drug development. We now have a credible, systematic way to bring SGK1 biology to bear on them, while our cardiac programs continue to move forward at full
More news about: Thryv Therapeutics Inc.
Sep 03, 2026, 16:22 ET American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of Sterility
provider.Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
More news about: American Regent, Inc.
Sep 03, 2026, 13:00 ET World Class Health Launches Infusion Care, Bringing Specialty Drug Treatments Home and Cutting Employer Costs by Roughly 46%
projected to rise another 32% by 2028. The same drug can cost several times more in a hospital outpatient suite than in a member's home, at an identical standard of care. Most members are referred directly
More news about: World Class Health
Sep 03, 2026, 12:23 ET Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
formulations launched in the EU and the United Kingdom. Its robust pipeline includes over 50 biosimilars, 130-plus innovative drugs and more than 200 generic drug candidates in-development.
More news about: Cipla
Sep 03, 2026, 11:43 ET HMP Global's Psych Congress Brings Marcus and Amber Capone, HHS Deputy General Counsel Matthew Zorn and Leading Clinicians Together for Five Days on the Future of Psychedelic Medicine
Global and President of HMP Education. "Psychedelic medicine is one part of that transformation, but it raises questions that go well beyond whether a drug is approved. Clinicians need to understand the evidence, the patients behind it and what these models of care could require. Psych Congress is where
More news about: HMP Global
Sep 03, 2026, 11:16 ET Kali Therapeutics Receives U.S. FDA Clearance for KT501 Investigational New Drug Application
pioneering next-generation immune-resetting and multi-specific therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for KT501. The clearance allows KT501 to advance into clinical evaluation in the United States.
More news about: Kali Therapeutics
Sep 03, 2026, 10:31 ET Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight
associated with tumor progression and metastasis; and Risvutatug Rezetecan, an antibody-drug conjugate (ADC) designed to deliver targeted cytotoxic activity to tumor cells.However, osteosarcoma drug development remains predominantly concentrated in early-stage clinical trials, particularly
More news about: DelveInsight Business Research, LLP
Sep 03, 2026, 10:28 ET Cellipont Bioservices' Texas Facility Has Supported Six Client Projects Expected to Reach IND Submission in 2026
manufacturing organization, today announced that its Texas facility has supported six client projects to date that are expected to reach Investigational New Drug application submission in 2026.
More news about: Cellipont Bioservices
Sep 03, 2026, 10:23 ET 에피백스, 면역원성 예측을 위한 AI 강화 모델 출시
ISPRI™에 대한 AI 기반 개선 사항의 출시를 발표했다. 이번 출시는 업데이트된 야누스매트릭스™(JanusMatrix™) 모델, 정제된 내성 조정 면역원성 점수 및 면역원성 위험에 대한 더 깊은 인사이트를 제공하도록 설계된 강화된 항약물항체(anti-drug antibody, ADA) 예측 모델을 도입한다.
More news about: EpiVax, Inc.
Sep 03, 2026, 10:11 ET AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact SueWallSt
alleges Aardvark Therapeutics made materially false or misleading statements regarding ARD-101's safety and tolerability, including claims that the drug was approximately 99% gut-restricted with limited systemic absorption and no serious adverse events, during the Class Period. When the voluntary Phase
More news about: SueWallSt.com
Sep 03, 2026, 10:07 ET WSE Shareholder Alert: September 29, 2026 Lead Plaintiff Deadline in Wise Group plc Securities Class Action - Contact SueWallSt
half a billion euros ($582.5 million) in suspicious transactions, with alleged links to fraud, corruption and drug trafficking. The complaint recounts that the probe had begun the prior year and was described as nearing completion.July 24, 2026 — The Charter
More news about: SueWallSt.com
Sep 03, 2026, 10:00 ET Nuffield Department of Medicine at the University of Oxford and 2U Launch New Program in AI-Driven Drug Discovery
Oxford AI in Drug Discovery and Medicine Programme, a six-week online executive education program that equips scientists, researchers, and R&D professionals to apply artificial intelligence across the drug discovery pipeline while navigating the ethical and
More news about: 2U
Sep 03, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
information about joining the class action]In late 2024, Capricor submitted its Biologics License Application ("BLA") to the U.S. Food and Drug Administration for Deramiocel as a cell therapy for the treatment of Duchenne muscular dystrophy. In July 2025, the FDA issued a Complete Response
More news about: Pomerantz LLP
Sep 03, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
2, 2026.Then, on May 14, 2026, Aardvark issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause." The press release
More news about: Pomerantz LLP
Sep 03, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wise Group plc of Class Action Lawsuit and Upcoming Deadlines - WSE
nearing completion, concerns potential money laundering offences, with alleged links to fraud, corruption and drug trafficking" and that "[p]rosecutors are investigating whether Wise Europe's services were used by international criminal organisations,
More news about: Pomerantz LLP
Sep 03, 2026, 10:00 ET TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare
More news about: TraceLink, Inc.
Sep 03, 2026, 10:00 ET TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare
More news about: TraceLink, Inc.